EUVIMEDEUVIMED entdecken
Open Access

Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy

Ting Dong iD, Huanmin Niu, Zhaojun Chu iD, Chengjun Zhou, Yinghui Gao, Mengqi Jia, Bin Sun iD, Xiaoxue Zheng, Wenru Zhang iD, Jiaozhen Zhang, Yanhai Luo, Yong Sun und 6 weitere

Science Advances · 2024

DOI: 10.1126/sciadv.adp4917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Ting Dong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Products & Chemical Biology of Ministry of Education, Institute of Medical Sciences, The Second Hospital of Shandong Univer…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Vesicular Transport Proteins, Protein Transport, Immunotherapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or programmed cell death-ligand 1 (PD-L1) have achieved impressive antitumor clinical outcomes. However, the limited response rates suggest the incomplete understanding of PD-L1 regulation. Here, we demonstrate that vacuole protein sorting 11 and 18 (VPS11/18), two key players in vesicular trafficking, positively regulate PD-L1 and confer resistance to immune checkpoint blockade therapy. VPS11/18 interact with PD-L1 in endosome recycling accompanied by promoting PD-L1 glycosylation and protein stability. VPS18 deficiency enhances antitumor immune response. Pharmacological inhibition by VPS18 inhibitor RDN impaired PD-L1 member trafficking and protein stability. Combination treatment of RDN and anti-cytotoxic T lymphocyte–associated antigen 4 synergistically enhances antitumor efficacy in aggressive and drug-resistant tumors. RDN exerted lung-preferred distribution and good bioavailability, suggesting a favorable drug efficacy. Together, our study links VPS18/11-mediated trans-Golgi network recycling of PD-L1 and points to a promising treatment strategy for the enhancement of antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenVesicular Transport ProteinsProtein TransportImmunotherapyHumansAnimalsMiceCell Line, TumorEndosomesImmune Checkpoint Inhibitors

Substanzen

B7-H1 AntigenVesicular Transport ProteinsCD274 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Natural Products & Chemical Biology of Ministry of Education, Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan, China.
  • Department of Natural Product Chemistry, Key Laboratory of Chemical Biology of Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, Shandong Province, China.
  • Department of Pathology/Urinary Surgery, The Second Hospital of Shandong University, Jinan, China.
  • National Glycoengineering Research Center, Shandong University, Jinan 250012, China.
  • Traditional Chinese Medicine Department, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, Shandong Province, China.

ORCID-Profile: Ting Dong, Zhaojun Chu, Bin Sun, Wenru Zhang, Hongxiang Lou, Huiqing Yuan

Zitieren

APA

Dong, T., Niu, H., Chu, Z., Zhou, C., Gao, Y., Jia, M., Sun, B., Zheng, X., Zhang, W., Zhang, J., Luo, Y., Sun, Y., Wang, C., Lu, Q., Liu, C., Shao, G., Lou, H., & Yuan, H. (2024). Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.adp4917

Vancouver

Dong T, Niu H, Chu Z, Zhou C, Gao Y, Jia M, et al. Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy. Science Advances. 2024. doi:10.1126/sciadv.adp4917

BibTeX
@article{Dong2024,
  author = {Dong, Ting and Niu, Huanmin and Chu, Zhaojun and Zhou, Chengjun and Gao, Yinghui and Jia, Mengqi and Sun, Bin and Zheng, Xiaoxue and Zhang, Wenru and Zhang, Jiaozhen and Luo, Yanhai and Sun, Yong and Wang, Chan and Lu, Qiqi and Liu, Changhong and Shao, Guangfeng and Lou, Hongxiang and Yuan, Huiqing},
  title = {Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adp4917}
}
Kostenlos starten →